Fosun Orinove PharmaTech

Fosun Orinove PharmaTech is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for oncology. A joint venture between Fosun Pharma and Orinove, the company leverages expertise in medicinal chemistry to target key pathways in cancer cell survival and proliferation, such as the BCL-2 family of proteins and various cyclin-dependent kinases. Its lead programs include dual BCL-2/BCL-xL inhibitors and selective CDK inhibitors designed to overcome resistance in both solid and hematological malignancies. The company is headquartered in Suzhou, China, and conducts clinical trials globally to address significant unmet needs in the cancer landscape.